GO
Loading...

Lightning Round OT: Amgen, Bank of America and More

Wednesday, 1 Dec 2010 | 7:31 PM ET
Lightning Round OT
You say the name of a stock, and Mad Money's Jim Cramer tells you whether to buy or sell.

Amgen : Celgene offers the growth that investors want, Cramer said. Amgen does not. He recommended buying CELG ahead of this weekend’s American Society of Hematology annual meeting.

Exelon : EXC underperformed its peers during the downturn and now continues to lag as the American economy improves. Why? Because investors sell the utilities in favor of growth names as the business cycle revs up. Cramer likes Exelon, and he endorsed the stock, but he wanted investors to know this before they buy it.

NYSE Euronext : “Good yield but … not a lot of growth,” Cramer said.

Bank of America : “It’s too cheap to sell,” Cramer said, but “it’s not going higher.”







When this story published, Cramer’s charitable trust owned Bank of America.

Call Cramer: 1-800-743-CNBC

Questions for Cramer? madmoney@cnbc.com

Questions, comments, suggestions for the Mad Money website? madcap@cnbc.com

  Price   Change %Change
AMGN
---
BAC
---
EXC
---
NYX
---

Featured

Contact Mad Money

  • Showtimes

    Monday - Friday 6p ET
  • Jim Cramer is host of CNBC's "Mad Money" and co-anchor of the 9 a.m. ET hour of CNBC's "Squawk on the Street."

Mad Money Features

  • Grab the latest CNBC gear from the NBCUniversal Store!

  • Get a behind-the-scenes look at how Cramer formulates his investment advice. "Inside the Madness" is a column, which features e-mails and more with Cramer and his researcher Nicole Urken.

  • You’ve always wanted to hit the “Hallelujah!” button. Here’s your chance.